Mar 28
2024
Looking Ahead: Precision Medicine Solutions Hold Increasing Promise for Healthcare Businesses
Precision medicine encompasses a broad spectrum of technologies, sciences, and programs that emphasize tailoring medicine to the individual. These capabilities can empower clinicians to optimize treatment pathways and drastically improve patient outcomes, but the healthcare industry’s adoption of precision medicine technology has historically lagged.
Joe Spinelli, chief strategy officer of Aranscia, shares his predictions on how precision medicine tools will become more widely adopted in 2024 and beyond and explains what it takes for organizations to implement these programs successfully.
How is precision medicine evolving and in which areas of healthcare will it be most utilized in 2024?
This is an exciting time for precision medicine, as some of the more foundational work that’s been done over the past several decades in genomics, diagnostics, and artificial intelligence is finding meaningful applications in population health, rare disease treatments, and oncology. The evolutions the healthcare industry is experiencing now are less about the core/novel methodologies and have more to do with the effective practical utilization of those methodologies at scale across the spectrum of care.
What are some of the biggest, most recent healthcare hurdles precision medicine can help mitigate?
The evolution of precision medicine involves two distinct yet equally important initiatives: the development of innovative technologies and therapies to improve care on an individualized basis, as well as the effective utilization of those innovations within clinical care settings. Democratizing access to these types of precision medicine solutions through technology and workflow implementation will be a key factor in the clinical and economic success of these programs.
How will precision medicine solutions benefit providers from a business perspective this year?
As more care cohorts are attached to value-based initiatives and/or care models, multi-step processes of candidate identification, intervention, and outcomes tracking become increasingly important for care organizations and vendors alike to align on. In addition, companion diagnostic and biomarker programs will help providers and payers better align the cost and appropriate therapeutic use of innovative offerings.